Cancer Drug Shortages This Week: How Patients Can Read FDA Updates

What the FDA page is actually telling you

The FDA runs a public drug shortage database. It is a real record, updated by the agency, and it is worth knowing how to read. It is also easy to misread.

Start with the definition. Federal law defines a drug shortage as a period when demand or projected demand for a drug within the United States exceeds supply. The FDA tracks this at the national level, using information manufacturers are required to send.

National is the key word. A drug can be listed as short while your infusion center has a full shelf. A drug can be absent from the list while your local pharmacy cannot get it. The FDA says so plainly: a pharmacy that cannot fill a prescription is often facing a temporary local distribution problem.

How a record is built

Each entry describes one package of one product from one company, not a drug in general. On August 6, 2026, the database held 35 separate entries for carboplatin injection alone, because different manufacturers and different vial sizes are tracked separately.

The fields that matter most:

• Status. Current, Resolved, or To Be Discontinued. On August 6, 2026, the whole database held 1,180 Current entries, 447 To Be Discontinued, and 24 Resolved.
• Availability. A per-package note such as Available or Unavailable. Two entries for the same drug can disagree, and that is not an error.
• Initial posting date. When that entry first appeared. Some run for years.
• Update type. New, or Reverified, meaning the FDA rechecked the entry with the company.
• Related info. The reason and the recovery estimate. A carboplatin entry that day read: estimated recovery TBD.
• Therapeutic category. Oncology entries numbered 81 that day, out of 1,180 current entries overall.

Four common misreadings

Resolved does not mean plentiful. It means the FDA judged that supply now meets national demand for that entry. Backlogs at individual pharmacies can outlast that date.

To Be Discontinued is not a shortage. It is a company saying it will stop making the product. Sometimes other makers absorb the volume without any gap.

One entry is not the market. If four companies make a drug and one reports a problem, the drug may still be widely available.

The list does not rank severity. A drug used by thousands daily and a drug used by a few hundred people a year look identical in the table.

The FDA also states that its own authority stops at supply. It has no power over drug pricing.

The disease behind one entry

Abstractions get clearer with a real drug. Azacitidine injection has been on the current oncology shortage list since December 2020.

NCI lists azacitidine as approved for certain myelodysplastic syndromes, which are bone marrow disorders where blood cells do not mature properly, including chronic myelomonocytic leukemia. It is also approved for some adults with acute myeloid leukemia, or AML, who reached a first complete remission after intensive induction therapy and cannot finish intensive curative therapy.

AML is a cancer of the blood and bone marrow, in which the marrow makes a large number of abnormal blood cells. It is the most common acute leukemia in adults, and it usually gets worse quickly without treatment.

How it shows up. NCI names fever, feeling tired, and easy bruising or bleeding as the signs. Smoking, past chemotherapy, and radiation exposure raise risk.

How it is diagnosed. Tests of the blood and bone marrow make the diagnosis. A bone marrow sample is taken and examined. AML is not staged the way solid tumors are. Instead, subtype and gene changes in the leukemia cells drive the plan.

How it is treated. Treatment usually runs in two phases. Remission induction therapy comes first, aiming to clear leukemia cells from blood and marrow. Consolidation therapy follows, aiming to kill cells that remain and could cause relapse.

Supportive care runs alongside both. Myelosuppression, meaning fewer red cells, white cells, and platelets, comes from the leukemia and from the chemotherapy. NCI lists red cell and platelet transfusions to replace destroyed cells, plus antibiotics and antifungals to prevent or treat infection.

How AML outcomes have moved

These are SEER figures for the whole US population. They are a group average, not a personal forecast.

For acute myeloid leukemia, five-year relative survival is 33.4 percent for cases from 2016 to 2022. An estimated 22,720 new cases and 11,500 deaths are projected for 2026. Median age at diagnosis is 70. In 1975 the five-year figure was under 6 percent, so the direction of travel is real even though the number is still hard.

When to call, and how fast

For someone with AML or in treatment for it, some symptoms are emergencies, not next-appointment items. Call the team the same day for:

• Fever of 100.5 degrees Fahrenheit — 38 °C is 100.4 °F; act at 100.4 °F —, or 38 degrees Celsius, or higher.
• Shaking chills.
• Bleeding that will not stop, or bruising with no cause.
• Blood in urine or stool, or black tarry stools.
• New shortness of breath, chest pain, or confusion.
• Sores or white coating in the mouth.

Infection during low blood counts can turn serious in hours. Our page on chemotherapy covers the counts cycle that drives that risk.

What to do with a shortage headline

Look up the drug in your own regimen, by name, in the FDA database. Read the status and the initial posting date. Then bring one question to the team: is the supply in this clinic affected, and what changes if it is.

If a substitute drug carries different cost or coverage, our guides to chemotherapy and financial assistance for cancer cover the next steps.

Sources

• FDA, Drug Shortages — https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
• FDA, Frequently Asked Questions about Drug Shortages — https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
• FDA Drug Shortages database — https://dps.fda.gov/drugshortages
• openFDA drug shortages API — https://api.fda.gov/drug/shortages.json
• NCI, Azacitidine — https://www.cancer.gov/about-cancer/treatment/drugs/azacitidine
• NCI PDQ, Acute Myeloid Leukemia Treatment (Patient Version) — https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
• SEER Cancer Stat Facts, Acute Myeloid Leukemia — https://seer.cancer.gov/statfacts/html/amyl.html
• NCI, Infection and Neutropenia during Cancer Treatment — https://www.cancer.gov/about-cancer/treatment/side-effects/infection